Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | TERT | O14746 | 5/20 | 0.46 |
| ▸ | TOP1 | P11387 | 4/20 | 0.45 |
| ▸ | CYCS | P99999 | 4/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL585886 | 0.99 | TERT (0.47) | ENPP2TERTTOP1CYCSABCG2 | |
| SCHEMBL12057426 | 0.93 | TERT (0.43) | ENPP2TERTTOP1CYCSABCG2 | |
| SCHEMBL12057450 | 0.93 | TERT (0.43) | ENPP2TERTTOP1CYCSABCG2 | |
| SCHEMBL12057451 | 0.93 | TERT (0.43) | ENPP2TERTTOP1CYCSABCG2 | |
| SCHEMBL12428034 | 0.93 | TERT (0.43) | ENPP2TERTTOP1CYCSABCG2 | |
| SCHEMBL12057441 | 0.93 | TERT (0.43) | ENPP2TERTTOP1CYCSABCG2 | |
| SCHEMBL12057400 | 0.93 | TERT (0.43) | ENPP2TERTTOP1CYCSABCG2 | |
| SCHEMBL12057440 | 0.93 | TERT (0.43) | ENPP2TERTTOP1CYCSABCG2 | |
| SCHEMBL12057448 | 0.93 | TERT (0.43) | ENPP2TERTTOP1CYCSABCG2 | |
| Hydrochloric Acid SCHEMBL2197145 | 0.92 | TERT (0.44) | ENPP2TERTTOP1CYCSABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084602-B2 | Porphyrin derivatives and their use in photodynamic therapy | DESTINY PHARMA LIMITED (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20070281915-A1 | Porphyrin Derivatives and Their Use in Photodynamic Therapy | DESTINY PHARMA LIMITED | 2007-12-06 | — | — | US | disclosed |
| US-7244841-B2 | Porphyrin derivatives and their use in photodynamic therapy | DESTINY PHARMA LIMITED (GB) | 2007-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281915-A1 | Porphyrin Derivatives and Their Use in Photodynamic Therapy | PPOX, PPIF, TYR | ENPP2 314/4885TERT 2287/4885TOP1 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.